JP2011529912A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529912A5
JP2011529912A5 JP2011521353A JP2011521353A JP2011529912A5 JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5 JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5
Authority
JP
Japan
Prior art keywords
peg
lipid
cholesterol
nanoparticle
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011521353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529912A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/052396 external-priority patent/WO2010014895A2/en
Publication of JP2011529912A publication Critical patent/JP2011529912A/ja
Publication of JP2011529912A5 publication Critical patent/JP2011529912A5/ja
Pending legal-status Critical Current

Links

JP2011521353A 2008-07-31 2009-07-31 核酸送達システム用のナノ粒子組成物 Pending JP2011529912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8528908P 2008-07-31 2008-07-31
US61/085,289 2008-07-31
PCT/US2009/052396 WO2010014895A2 (en) 2008-07-31 2009-07-31 Nanoparticle compositions for nucleic acids delivery system

Publications (2)

Publication Number Publication Date
JP2011529912A JP2011529912A (ja) 2011-12-15
JP2011529912A5 true JP2011529912A5 (enExample) 2012-07-26

Family

ID=41610973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521353A Pending JP2011529912A (ja) 2008-07-31 2009-07-31 核酸送達システム用のナノ粒子組成物

Country Status (6)

Country Link
US (1) US20110111044A1 (enExample)
EP (1) EP2304026A4 (enExample)
JP (1) JP2011529912A (enExample)
CA (1) CA2731173A1 (enExample)
TW (1) TW201004658A (enExample)
WO (1) WO2010014895A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103528A2 (en) * 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
JP2013524811A (ja) * 2010-04-20 2013-06-20 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド ナノザイム、ナノザイムの製造方法、およびナノザイムの使用方法
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8709466B2 (en) 2011-03-31 2014-04-29 International Business Machines Corporation Cationic polymers for antimicrobial applications and delivery of bioactive materials
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2915300A1 (en) * 2012-11-02 2015-09-09 Telefonaktiebolaget L M Ericsson (Publ) Network node, user node and methods for channel estimation
JP6360074B2 (ja) * 2013-01-03 2018-07-18 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチCouncil Of Scientific & Industrial Research マンノース受容体選択的リシニル化カチオン性両親媒性物質及びその調製方法
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
PL3019619T3 (pl) * 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
WO2015023715A1 (en) 2013-08-14 2015-02-19 The University Of Florida Research Foundation, Inc. Nanozymes, methods of making nanozymes, and methods of using nanozymes
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
EP4101930A1 (en) 2015-09-17 2022-12-14 ModernaTX, Inc. Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CN107951862B (zh) * 2016-10-17 2021-03-12 南京绿叶制药有限公司 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
CA3071968A1 (en) 2017-08-04 2019-02-07 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticle
CN111971066B (zh) * 2018-01-18 2025-03-11 伊泽阿恩埃免疫疗法股份有限公司 脂质纳米颗粒
US20210261964A1 (en) * 2018-07-19 2021-08-26 The Research Foundation For Microbial Diseases Of Osaka University LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CN109549934B (zh) * 2018-12-25 2021-03-09 上海交通大学 一种多糖基脂质纳米粒子的制备方法
KR20240027630A (ko) * 2021-06-01 2024-03-04 나노베이션 테라퓨틱스 인크. 지질 나노입자를 사용한 dna 벡터 전달
TWI851090B (zh) * 2022-03-17 2024-08-01 國立成功大學 雙股寡去氧核苷酸、包含該雙股寡去氧核苷酸的組合物及其用途
EP4248949B1 (en) 2022-03-21 2024-08-28 R.G.C.C. Holdings AG Liposomal compositions
KR20240157096A (ko) 2022-03-23 2024-10-31 나노베이션 테라퓨틱스 인크. 고 스테롤-함유 지질 나노입자
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
JP7557915B2 (ja) * 2022-10-18 2024-09-30 株式会社チップトン テイラー反応装置及びカプセル粒子の製造方法
CN121568686A (zh) * 2023-07-24 2026-02-24 北京生命科学研究所 用于皮肤疾病局部治疗的脂质纳米颗粒组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
CA2256900A1 (en) * 1996-05-29 1997-12-04 Xiao-Ying Meng Cationic polymer/lipid nucleic acid delivery vehicles
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080207542A1 (en) * 2002-03-26 2008-08-28 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2597724A1 (en) * 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
WO2007090194A2 (en) * 2006-02-01 2007-08-09 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties

Similar Documents

Publication Publication Date Title
JP2011520983A5 (enExample)
JP5795072B2 (ja) Rna干渉を誘導する核酸分子及びその用途
JP2012509258A5 (enExample)
CA2859127C (en) Novel oligonucleotide conjugates and use thereof
US9006191B2 (en) Silencing of polo-like kinase expression using interfering RNA
KR101752812B1 (ko) 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법
JP2012509272A5 (enExample)
JP2012509366A5 (enExample)
JP2012509273A5 (enExample)
ES2809481T3 (es) Estructura de oligonucleótidos de tipo nanopartícula mejorada que tiene alta eficiencia y método para preparar la misma
JP2015518373A5 (enExample)
JP2014530602A (ja) アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法
JP2015502365A5 (enExample)
WO2015082080A1 (en) Means for lung specific delivery
JP2011509258A5 (enExample)
Bhavsar et al. Translational siRNA therapeutics using liposomal carriers: prospects & challenges
KR102701681B1 (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
CN107951862B (zh) 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
JP2025540278A (ja) 修飾免疫調節薬
WO2023168202A2 (en) Certain dux4 inhibitors and methods of use thereof
CN120077134A (zh) 靶向apoc3的多核酸分子及其用途
CN107630015B (zh) 一种稳定的dna-rna双链结构
Zhang Anti-miRNA Delivery Systems Based on Self-assembled Nanostructure
AU2013202970A1 (en) Silencing of polo-like kinase expression using interfering RNA